

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 July 2022 (07.07.2022)



(10) International Publication Number
WO 2022/147532 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 35/00 (2006.01)

A61K 47/68 (2017.01)

(21) International Application Number:

PCT/US2022/011119

(22) International Filing Date:

04 January 2022 (04.01.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/133,707 04 January 2021 (04.01.2021) US

63/172,968 09 April 2021 (09.04.2021) US

(71) Applicant: MERSANA THERAPEUTICS, INC.

[US/US]; 840 Memorial Drive, Cambridge, Massachusetts 02139 (US).

(72) Inventors: LOWINGER, Timothy B.; 352 School Street,

Carlisle, Massachusetts 01741 (US). CHIN, Chen-Ni;

24B Weston Ave., Somerville, Massachusetts 02144 (US).

DAMELIN, Marc I.; 42 Lexington Avenue, Needham, Massachusetts 02494 (US). TOADER, Dorin; 1699 Cambridge Street, Apt. 32, Cambridge, Massachusetts 02138 (US).

(74) Agent: ERLACHER, Heidi et al.; Cooley LLP, 1299 Pennsylvania Ave, NW, Suite 700, Washington, District of Columbia 20004 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: B7H4-TARGETED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF



(57) Abstract: The present disclosure relates generally to antibody-drug conjugates comprising monoclonal antibodies that specifically bind the human B7-H4 in soluble form, or membrane bound (*i.e.*, when expressed on a cell surface) and to methods of using these conjugates as therapeutics and/or diagnostics.

WO 2022/147532 A1

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*